论文部分内容阅读
一、森永乳业公司推出白血球减少症治疗药leukoprol注射液其为世界首创的M—CSF制剂。特征:在巨噬细胞作用下,增加生理性白细胞数量,促进骨髓移植后白细胞数加,对于癌症患者化学疗法后可以缩短白细胞数量回复的天数。二、藤泽制药公司研究的免疫抑制剂FK—506于1993年3月4日得到厚生省认可,试验号为FK—506,并预定于4月向德国、5月向法国、秋季向美国提出试验
First, Morinaga dairy company launched leukoprol treatment of leukopenia injection of the world’s first M-CSF preparation. Features: Under the action of macrophages, increase the number of white blood cells and promote the number of leukocytes after bone marrow transplantation, for cancer patients can reduce the number of days after chemotherapy leukocyte recovery. Second, the Fujitsu pharmaceutical company’s immunosuppressive agent FK-506 was approved by the Ministry of Health and Welfare on March 4, 1993, the test number is FK-506, and is scheduled to Germany in April to France in May, autumn to the United States put forward the test